{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/understanding-alcohol-associated-liver-disease-focus-alcohol-associated-hepatitis#webpage",
"url": "https://www.fortrea.com/insights/understanding-alcohol-associated-liver-disease-focus-alcohol-associated-hepatitis",
"name": "Understanding alcohol-associated liver disease: a focus on alcohol-associated hepatitis",
"description": "Explore this Fortrea white paper on alcohol-associated liver disease clinical trials and discover how evolving research strategies are helping advance ALD drug development and therapeutic innovation for patients with alcohol-related liver diseases. The white paper examines key challenges and opportunities in alcohol-associated liver disease clinical development, including alcoholic hepatitis research, liver fibrosis progression, cirrhosis-related complications, patient recruitment and retention challenges, biomarker development, endpoint selection, and hepatology-focused clinical trial design. Learn how emerging therapies for alcohol-associated liver disease, adaptive clinical development strategies, liver disease biomarkers, evidence-generation approaches, and improved patient-focused research models are helping organizations strengthen liver disease clinical trials, improve study execution, and support the advancement of innovative treatments for alcoholic hepatitis and advanced alcohol-related liver disease."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Understanding alcohol-associated liver disease: a focus on alcohol-associated hepatitis",
"item": "https://www.fortrea.com/insights/understanding-alcohol-associated-liver-disease-focus-alcohol-associated-hepatitis"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/understanding-alcohol-associated-liver-disease-focus-alcohol-associated-hepatitis#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/understanding-alcohol-associated-liver-disease-focus-alcohol-associated-hepatitis#webpage"
},
"headline": "Understanding alcohol-associated liver disease: a focus on alcohol-associated hepatitis",
"description": "Explore this Fortrea white paper on alcohol-associated liver disease clinical trials and discover how evolving research strategies are helping advance ALD drug development and therapeutic innovation for patients with alcohol-related liver diseases. The white paper examines key challenges and opportunities in alcohol-associated liver disease clinical development, including alcoholic hepatitis research, liver fibrosis progression, cirrhosis-related complications, patient recruitment and retention challenges, biomarker development, endpoint selection, and hepatology-focused clinical trial design. Learn how emerging therapies for alcohol-associated liver disease, adaptive clinical development strategies, liver disease biomarkers, evidence-generation approaches, and improved patient-focused research models are helping organizations strengthen liver disease clinical trials, improve study execution, and support the advancement of innovative treatments for alcoholic hepatitis and advanced alcohol-related liver disease.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-15",
"dateModified": "2024-10-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/WP_0049_Alcohol%20Liver%20Disease_0624_HiRes.pdf",
"encodingFormat": "application/pdf"
}
}
]
}